SOTIO Advances Colorectal Cancer ADC Program, SOT109, and Licenses Fully Human Antibodies from Biocytogen for Novel Tumor Target
- SOT109 will leverage antibodies generated with Biocytogen’s proprietary RenMabTM platform as backbone of ADC for colorectal cancer and other gastrointestinal cancers;
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced the licensing of fully human antibodies from Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics. The license will be used to develop an innovative antibody drug conjugate (ADC) for a novel tumor target under the option and license agreement established between the companies. The antibody selected will support the development of SOT109, SOTIO’s new ADC candidate, for the treatment of colorectal cancer and other gastrointestinal (GI) cancers.
SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline
- Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen’s proprietary RenLite® platform;
- Agreement will enable SOTIO to significantly broaden its next-generation ADC portfolio, including multi-specific ADCs;
- Biocytogen will receive an upfront payment and potential development milestone payments totaling up to $325.5 million;
SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology
- SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs to address indications with high unmet medical need.
- Collaboration bolsters SOTIO’s wider portfolio of differentiated immuno-oncology therapies tailored to address the specific challenges of solid tumors.
- Synaffix will receive an upfront payment and potential development milestone payments totaling $740 million.
SOTIO Biotech B.V.
Zuidplein 168
1077 XV Amsterdam
Netherlands
Zuidplein 168
1077 XV Amsterdam
Netherlands
SOTIO Biotech a.s.
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
SOTIO Biotech AG
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
SOTIO Biotech Inc.
180 Canal St., Suite 300
Boston, MA 02114
USA
180 Canal St., Suite 300
Boston, MA 02114
USA
